Advisory Board

Our advisors were chosen to bring Sustain Biotech unique perspectives and ideas in Smart BiomaterialsTM.

Our Advisory Board

Our scientific experts bring world-class expertise in clinical medicine, materials science, animal health, and clinical medicine. Our business advisors bring us important insights in finance, FDA regulations, and growth. The advisory board, working in tandem with our leadership team, sets our product, development and growth strategies.

David Calkins, Ph.D.

Dr. David Calkins is the Vice Chairman and Director for Research for the Vanderbilt Eye Institute. Dr. Calkins also has a leading role in the creation of initiatives in regenerative medicine across multiple disciplines at Vanderbilt University. Dr. Calkins is a leading authority on regenerative medicine in neuroscience, including “Smart Biomaterials,” as well as ophthalmic research on regenerative medicine for retinal conditions. Dr. Calkins provides Sustain a unique perspective on emerging technologies in health care and engineered materials.

Outi Hovatta, M.D., Ph.D.

Dr. Outi Hovatta is a leading Karolinska Institute scholar, and has been a leader in the development of stem cell lines used for clinical trials and research. She is also heavily involved in the development of both natural and man-made scaffolds used as structures for various stem cell therapies. Dr. Hovatta provides Sustain Biotech with unparalleled access to one of the leading medical research entities in the world, and unique insights into combinations of natural (collagen) and man-made materials.

Henry M. Spotnitz, M.D.

Henry M. Spotnitz, M.D. Is the Vice-Chairman, Research & Information Systems, Department of Surgery, and Director, Cardiovascular Surgery Research Lab at Columbia University and affiliated with New York Presbyterian/Columbia Hospital. He is Board certified in Thoracic Surgery and Surgery and is the first George H Humphrey’s II Professor of Surgery at Columbia. Dr. Spotnitz provides Sustain with important access to resources and initiatives at prestigious academic institutions and globally renowned hospitals.

Ron Schultz, Ph.D.

Dr. Ron Schultz is the Chair of the University of Wisconsin’s Department of Pathobiological Sciences in the University’s School of Veterinary Medicine. He is a recognized expert in diseases of domestic cattle. He has published extensively on the immunology, immunomodulators, and immunopathology of diseases such as Bovine Spongiform Encephalopathy. Dr. Schultz brings both a researcher’s perspective, as well as a practical view, as he is a long time operator of closed bovine herds.

John Byers

John Byers is an experienced advisor, specializing in business, mergers and acquisitions and securities matters. John currently provides advisory and consulting services to a number of businesses. Prior to that, Mr. Byers previously served as President and Chief Executive Officer of FPIC Insurance Group, Inc., a publicly traded insurance holding company, which he led until its successful sale in 2011. In addition to his leadership of FPIC, John has served on the boards and board committees of various other business and related organizations over the past several years. Mr. Byers provides Sustain Biotech guidance on a range of business, governance and legal matters.

Tom Lytle, BBA, MBA

Tom Lytle is a very experienced pharmaceuticals and biotech executive. Mr. Lytle’s career includes senior management positions with Pfizer and Amgen, along with a series of groundbreaking startup biotech companies, including Melanovus Oncology, Cytogen Corporation and Neogenix Oncology.  Tom has broad experience in sales, marketing and business development, and provides important guidance for Sustain Biotech’s emerging product lines.